Replies to post #33365 on Anavex Life Sciences Corp (AVXL)

[imho]

This quote from Dr. Missling in this morning's press release really stood out to me along with a number of other great quotes:

“While we remain focused on Alzheimer’s, the remarkably fast onset of clinical effect of ANAVEX 2-73 increases our options to potentially pursue additional indications for diseases characterized by working memory impairment and may enable clinical trials to be completed within shorter time frames.” [emphasis added]

Could this be hinting at a fast track designation for Parkinsons, Epilepsy, Alzheimers, or?

Could be. But I recall Dr. Missling mentioning that he was hoping to go into a P3 with as few as 100-300 patients. Does anyone recall this? I may very well be wrong.

IMHO